Evidence map›Paper›PMID 33364947›Full record

Trial reportFrontiers in pharmacology2020

Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial.

Yinjuan Li, Lu Qi, Haihong Bai, Ying Liu, Rongxia Fan, Yongrui Tu, Yongqiang Sun, Juxiang Wang, Qi Qi, Xiaohui Feng and 2 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yinjuan LiDepartment of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Lu QiDepartment of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Haihong BaiDepartment of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Ying LiuDepartment of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Rongxia FanDepartment of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yongrui TuChangzhou Siyao Pharmaceuticals Co., Ltd., Jiangsu, China.
Yongqiang SunChangzhou Siyao Pharmaceuticals Co., Ltd., Jiangsu, China.
Juxiang WangChangzhou Siyao Pharmaceuticals Co., Ltd., Jiangsu, China.
Qi QiChangzhou Siyao Pharmaceuticals Co., Ltd., Jiangsu, China.
Xiaohui FengChangzhou Siyao Pharmaceuticals Co., Ltd., Jiangsu, China.
Da ZhouChangzhou Siyao Pharmaceuticals Co., Ltd., Jiangsu, China.
Xinghe WangDepartment of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Beijing Shijitan Hospital · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bioequivalencefood effecthighly variable drugpharmacokineticrasagiline

Identifiers

PMID33364947
PMCPMC7750811
OpenAlexW3109887631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.